𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment, Rationale, and Study Design of TALISMAN Study: A Randomized Phase II Open-Label Study of Second-line Erlotinib Versus Intermittent Erlotinib Dosing With Docetaxel in the Treatment of Former-Smoker Men Affected by Recurrent Squamous Non–Small-Cell Lung Cancer

✍ Scribed by Cesare Gridelli; Antonio Rossi; Paola Venturino; Filippo de Marinis

Book ID
115076799
Publisher
CIG Media Group, LP.
Year
2011
Tongue
English
Weight
101 KB
Volume
12
Category
Article
ISSN
1525-7304

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An International, Multicenter, Randomize
An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial
✍ Cesare Gridelli; Charles Butts; Fortunato Ciardiello; Ronald Feld; Ciro Gallo; F 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 91 KB